REGULATORY

• Post-Launch Price Correction Floated for Imported Drugs 1st Approved in Japan: Chuikyo
  April 13, 2017

• Average Price of Drugs Prescribed to Outpatients Rising Due to Increase in Number of High-Priced Drugs: CEFP Working Group
  April 13, 2017

• Rebates, Allowances Come Up in CEFP Social Security Working Group’s Analysis of Current State of Wholesalers
  April 13, 2017

• Xarelto Survey Scandal “Very Regrettable”: Shiozaki
  April 12, 2017

• CEFP Social Security Working Group Raises Questions on Price Maintenance Premium, Biosimilar Policy
  April 12, 2017

• MHLW to Continue Withholding HPV Vaccine Recommendation
  April 11, 2017

• 41 New APIs Approved in FY2016 in Japan: PMDA
  April 11, 2017

• MHLW Advisory Panel to Review Mundipharma’s Injectable Pralatrexate on April 21
  April 11, 2017

• Certified IRBs to Review How Monitoring/Audits Will Be Conducted for “Specified Clinical Research”: Official
  April 10, 2017

• MHLW to Mull Use of Data from “Specified Clinical Research” for Drug Review: Official
  April 10, 2017

• Clinical Research Bill Passed into Law
  April 7, 2017

• Ex-Min. Tamura’s Study Group Boots Up with Backing of 17 Healthcare-Related Organizations
  April 7, 2017

• Domestic Drug Production Logs 1st Rise in 4 Years: 2015 MHLW Survey
  April 6, 2017

• Rare Symposium Planned after Closed-Door Regulatory Head Confab in October
  April 6, 2017

• AMED Inks Collaboration Pact with Spanish Authority
  April 6, 2017

• “I Don’t Use Biosimilars,” Says Ex-Chief of Japan College of Rheumatology
  April 5, 2017

• MHLW Releases “Blue Book” Generic Data List
  April 4, 2017

• MHLW Sets Up Office for Startup Support, Starts Receiving Applications for Consultations
  April 4, 2017

• MHLW Issues Optimal Use Guidelines for Repatha, Praluent
  April 3, 2017

• MHLW to Launch Conditional Early Approval for Medical Devices Too
  April 3, 2017

ページ

• « 先頭
• ‹ Prev
• …
• 248
• 249
• 250
• 251
• 252
• 253
• 254
• 255
• 256
• …
• Next ›
• 最終 »